trial-leads-to-fda-approval-of-drug-for-rare,-deadly-blood-cancer

Less than 50% of individuals diagnosed with an uncommon blood cancer subtype live longer than a year. A clinical trial spearheaded by Stanford Medicine has resulted in FDA endorsement of a novel therapy that offers the potential to enhance survival rates.


Leave a Reply

Your email address will not be published. Required fields are marked *

Share This